New York University

Spheryx, Inc.

Kent Kirshenbaum

Timothy W Craven

Paul Michael Levine

Justin M Holub

Sung Bin Shin

Richard Bonneau

David G Grier

Fook Chiong Cheong

Michael J Garabedian

Martin J Sadowski

Jeffrey A Schneider

Mia L Huang

Kaitlynn Snyder

Lauren E Altman

Susan Logan

Amanda Kasper

Rushna Quddus

Provided are peptoid-peptide macrocycles. The peptoid-peptide macrocycles may have inhibitory activity towards the Wnt signaling pathway. The Wnt signaling pathway is associated with cancer and other diseases and conditions. Such diseases include, for example, pulmonary fibrosis. Also described are methods of making the peptoid-peptide macrocycles, compositions containing the peptoid-peptide macrocycles, and methods of using the peptoid-peptide macrocycles.

Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same

An in-line holographic microscope can be used to analyze a video stream to track individual colloidal particles' three-dimensional motions. The system and method can provide real time nanometer resolution, and simultaneously measure particle sizes and refractive indexes. An assay using the holographic microscope for holographic particle characterization directly detect viruses, antibodies and related targets binding to the surfaces of specifically functionalized micrometer-scale colloidal probe beads. The system detects binding of targets by directly measuring associated changes in the bead's diameter without the need for downstream labeling and analysis.

Automated holographic video microscopy assay

Novel peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: The peptoid oligomers are prepared as modulators of androgen receptor (AR), and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with unwanted or aberrant AR activity. The present peptoid oligomers are particularly valuable for the treatment of subjects with cancer.

Multivalent peptoid oligomers, pharmaceutical compositions and methods of using same

Miniature protein scaffolds and compositions thereof (e.g., vaccine formulations) and methods of using same are described herein. In a particular embodiment, the miniature protein scaffold comprises an isolated &#x3b2;-strand connected via a loop to a left-handed poly proline type-II (PPII) helix formed in the absence of proline residues.

Miniature protein scaffolds and methods for use thereof

Novel hybrid polymers are disclosed that have a structure represented by the following formula I: wherein Abiotic oligomer, Polypeptide, X, Y, and Rare as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.

Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same

Novel methods to prepare novel polymers are disclosed. Oxazolidinyl compounds according to formula IV: are also disclosed as intermediate compounds that can be reacted with an acid to form a polymer of formula I.

Polymers, pharmaceutical compositions and methods of synthesizing the same

Novel peptoid oligomers are disclosed that have a formula represented by the following formula I: wherein Rand n are as described herein. The peptoids demonstrate antimicrobial and antimalarial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial or malarial infection is involved. The present cyclic peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.

Cyclic peptoid oligomers, pharmaceutical compositions and methods of using the same

Novel peptoid oligomers are disclosed that have a formula represented by the following formula I:  The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present cyclic and linear peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.

Peptoid oligomers, pharmaceutical compositions and methods of using the same

Novel hybrid polymers are disclosed that have a structure represented by the following wherein Abiotic oligomer, Polypeptide, X, Y, and Rare as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.

Novel peptide/peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: The peptide/peptoid oligomers demonstrate the ability to inhibit fibrillization and oligomerization of A&#x3b2; and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with A&#x3b2; oligomerization. The present peptidomimetic oligomers are particularly valuable for the treatment of subjects with AD.

Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same

Novel peptoid oligomers are disclosed that have a formula represented by the following formula I: The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present cyclic and linear peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.

The present invention relates to novel complex peptidomimetic products comprising multiple homogeneous or heterogeneous pendant groups that are site-specifically positioned along a linear oligomer or polymer scaffold and methods of making thereof. More specifically, the invention relates to N-substituted glycine peptoid oligomers or peptoids and their use as substrates for azide-alkyne[3+2]-cycloaddition conjugation reactions and subsequent additional rounds of oligomerization and cycloaddition. The methods of the invention may also be used to generate peptoid-peptide hybrid or peptide products comprising multiple homogeneous or heterogeneous pendant groups, which are positioned precisely along the linear oligomer or polymer scaffold.

Method for site-specific polyvalent display on polymers

The present invention relates to novel complex peptidomimetic products comprising multiple homogeneous or heterogeneous pendant groups that are site-specifically positioned along a linear oligomer or polymer scaffold and methods of making thereof. More specifically, the invention relates to N-substituted glycine peptoid oligomers or peptoids and their use as substrates for azide-alkyne [3+2]-cycloaddition conjugation reactions and subsequent additional rounds of oligomerization and cycloaddition. The methods of the invention may also be used to generate peptoid-peptide hybrid or peptide products comprising multiple homogeneous or heterogeneous pendant groups, which are positioned precisely along the linear oligomer or polymer scaffold.

Growing community of inventors

New York, NY, United States of America

Kent Kirshenbaum